Colorectal Cancer

Foreign-born individuals who recently immigrated to the United States had lower adherence to colorectal cancer screening than foreign-born individuals who have lived in the U.S. longer and those born in the country, data show.

Circulating tumor DNA testing appeared to identify risk for recurrence among patients with stage II to stage IV colorectal cancer, according to study results published in Nature Medicine.

CMS has announced expanded coverage for specific colorectal cancer screening tests by lowering the minimum age to include individuals aged 45 years and older under Medicare Part B.

A greater percentage of colorectal cancer cases in the United States are being diagnosed at advanced stages, according to an American Cancer Society report.

In this video interview, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed the SUNLIGHT trial data presented at ASCO Gastrointestinal Cancers Symposium.

A phase 3 trial of trilaciclib in combination FOLFOXIRI and bevacizumab for patients with metastatic colorectal cancer met its co-primary endpoints but will be terminated based on early efficacy data, according to the agent’s manufacturer.

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed the mature phase 3 data on the addition of bevacizumab to trifluridine/tipiracil in refractory colorectal cancer in a video interview with Healio.

In a video interview with Healio, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about “the first combination to show efficacy in colorectal cancer in a specialized population.”

Geneoscopy announced it submitted an FDA premarket approval application for the noninvasive, stool-based, at-home screening test for colorectal cancer and advanced adenomas, according to a company release.

Moderate exercise may improve longevity for patients with colorectal cancer by acting on the gut microbiome, according to a study published in American Journal of Cancer Research.